Government Owned Inventions Available for Licensing, 17495 [2024-05038]

Download as PDF Federal Register / Vol. 89, No. 48 / Monday, March 11, 2024 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Emerging Imaging Technologies and Applications. Date: March 26, 2024. Time: 1:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health Rockledge II 6701 Rockledge Drive Bethesda, MD 20892, (Virtual Meeting). Contact Person: Zheng ‘‘Jane’’ Li, Ph.D., Scientific Review Officer, The Center for Scientific Review, The National Institutes of Health, 6701 Rockledge Drive Bethesda, MD 20892, 301–594–3385, zheng.li3@nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: March 5, 2024. David W. Freeman, Supervisory Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–05075 Filed 3–8–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES ddrumheller on DSK120RN23PROD with NOTICES1 National Institutes of Health Government Owned Inventions Available for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. SUMMARY: VerDate Sep<11>2014 18:24 Mar 08, 2024 Jkt 262001 Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing opportunity should be directed to: Suna Gulay French, Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center, Email: suna.gulay@ nih.gov or Phone: 240–276–7424. SUPPLEMENTARY INFORMATION: NIH Reference Number: E–153–2016– 0. Title: T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors. Intellectual Property US Provisional Application 62/327,529 filed April 26, 2016 PCT Application PCT/US2017/027865 filed April 17, 2017 US Patent 11,352,410 issued June 7, 2022 European Patent 3448882 issued November 24, 2021, validated in Switzerland, Germany, Belgium, Denmark, Spain, Finland, France, United Kingdom, Ireland, Italy, The Netherlands, Norway, Sweden Australian Patent Application 2017258745 filed October 19, 2018 Canadian Patent Application 3021898 filed April 17, 2017 17495 attractive target for T-cell based, anticancer therapies. Researchers at the NCI seek licensing and/or co-development research collaborations for T-cell immunotherapy that targets KK–LC–1 for use in the treatment of epithelial cancers. Therapeutic Area(s): Cancer. Competitive Advantages: Differential expression profile of KK–LC–1 suggests that therapy with a specific KK–LC–1 TCR could be cancer-specific and would not damage normal tissues; The repertoire of targetable epithelial antigens for TCR–T cell therapy is larger than for CAR–T cells; Increased sensitivity may improve tumor cell detection and killing versus CAR–T cells, due to lower epitope density required for activation; Higher avidity and lower affinity could result in each TCR–T cell destroying numerous antigen-presenting cancer cells; Thousands of cancer patients each year with otherwise untreatable disease may be eligible for immunotherapy with this TCR. Achieving expeditious commercialization of federally funded research and development is consistent with the goals of the Bayh-Dole Act, codified as 35 U.S.C. 200–212 and 37 CFR 404.4. Development Stage: Clinical Phase I. Dated: March 5, 2024. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2024–05038 Filed 3–8–24; 8:45 am] BILLING CODE 4140–01–P Technology Summery Metastatic cancers cause up to 90% of cancer deaths, yet few treatment options exist for patients with metastatic disease. Adoptive transfer of T cells that express tumor-reactive T-cell receptors (TCRs) has been shown to mediate regression of metastatic cancers in some patients. Unfortunately, identification of antigens expressed solely by cancer cells and not normal tissues has been a major challenge for the development of T-cell based immunotherapies. Thus, it is essential to find novel target antigens differentially expressed in cancer versus normal tissues. Inventors at the National Cancer Institute (NCI) have developed a TCR that specifically targets the Kita-Kyushu Lung Cancer Antigen 1 (KK–LC–1) 52– 60 epitope. KK–LC–1 antigen (encoded by the CT83 gene) is highly expressed by several common and aggressive epithelial tumor types. Importantly, KK–LC–1 is expressed at very low levels in normal tissues and not in those tissues vital for survival. This expression profile makes KK–LC–1 an PO 00000 Frm 00124 Fmt 4703 Sfmt 4703 DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2024–0050] National Navigation Safety Advisory Committee Meeting; April 2024 Meeting U.S. Coast Guard, Department of Homeland Security. ACTION: Notice of open Federal advisory committee meetings. AGENCY: The National Navigation Safety Advisory Committee (Committee) will conduct a series of meetings over 2 days in Bronx, New York to discuss matters relating to maritime collisions, allisions, and groundings; Inland Rules of the Road; International Rules of the Road; navigation regulations and equipment; routing measures; marine information; and aids to navigation systems. All meetings will be open to the public. DATES: SUMMARY: E:\FR\FM\11MRN1.SGM 11MRN1

Agencies

[Federal Register Volume 89, Number 48 (Monday, March 11, 2024)]
[Notices]
[Page 17495]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-05038]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government Owned Inventions Available for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing 
opportunity should be directed to: Suna Gulay French, Ph.D., Technology 
Transfer Manager, NCI, Technology Transfer Center, Email: 
[email protected] or Phone: 240-276-7424.

SUPPLEMENTARY INFORMATION: 
    NIH Reference Number: E-153-2016-0.
    Title: T-Cell Immunotherapy that Targets Aggressive Epithelial 
Tumors.

Intellectual Property

US Provisional Application 62/327,529 filed April 26, 2016
PCT Application PCT/US2017/027865 filed April 17, 2017
US Patent 11,352,410 issued June 7, 2022
European Patent 3448882 issued November 24, 2021, validated in 
Switzerland, Germany, Belgium, Denmark, Spain, Finland, France, United 
Kingdom, Ireland, Italy, The Netherlands, Norway, Sweden
Australian Patent Application 2017258745 filed October 19, 2018
Canadian Patent Application 3021898 filed April 17, 2017

Technology Summery

    Metastatic cancers cause up to 90% of cancer deaths, yet few 
treatment options exist for patients with metastatic disease. Adoptive 
transfer of T cells that express tumor-reactive T-cell receptors (TCRs) 
has been shown to mediate regression of metastatic cancers in some 
patients. Unfortunately, identification of antigens expressed solely by 
cancer cells and not normal tissues has been a major challenge for the 
development of T-cell based immunotherapies. Thus, it is essential to 
find novel target antigens differentially expressed in cancer versus 
normal tissues.
    Inventors at the National Cancer Institute (NCI) have developed a 
TCR that specifically targets the Kita-Kyushu Lung Cancer Antigen 1 
(KK-LC-1) 52-60 epitope. KK-LC-1 antigen (encoded by the CT83 gene) is 
highly expressed by several common and aggressive epithelial tumor 
types. Importantly, KK-LC-1 is expressed at very low levels in normal 
tissues and not in those tissues vital for survival. This expression 
profile makes KK-LC-1 an attractive target for T-cell based, anti-
cancer therapies.
    Researchers at the NCI seek licensing and/or co-development 
research collaborations for T-cell immunotherapy that targets KK-LC-1 
for use in the treatment of epithelial cancers.
    Therapeutic Area(s): Cancer.
    Competitive Advantages: Differential expression profile of KK-LC-1 
suggests that therapy with a specific KK-LC-1 TCR could be cancer-
specific and would not damage normal tissues; The repertoire of 
targetable epithelial antigens for TCR-T cell therapy is larger than 
for CAR-T cells; Increased sensitivity may improve tumor cell detection 
and killing versus CAR-T cells, due to lower epitope density required 
for activation;
    Higher avidity and lower affinity could result in each TCR-T cell 
destroying numerous antigen-presenting cancer cells; Thousands of 
cancer patients each year with otherwise untreatable disease may be 
eligible for immunotherapy with this TCR.
    Achieving expeditious commercialization of federally funded 
research and development is consistent with the goals of the Bayh-Dole 
Act, codified as 35 U.S.C. 200-212 and 37 CFR 404.4.
    Development Stage: Clinical Phase I.

    Dated: March 5, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2024-05038 Filed 3-8-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.